SCHEMBL4743364

SCHEMBL4743364

CC(C)CN(NC(=O)c1ccccc1)C(N)=S

nearest known ligand 0.71

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
POLB P06746 1/20 0.41
HTT P42858 1/20 0.40
RECQL P46063 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HPGD P15428 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
GAA P10253 2/20 0.39
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4747654 0.84 HDAC1 (0.46) ALDH1A1SMN1; SMN2RAB9ANPC1HDAC1
SCHEMBL9824905 0.83 POLB (0.51) ALDH1A1SMN1; SMN2RAB9ANPC1POLB
SCHEMBL5457229 0.73 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2HTTTDP1L3MBTL1
SCHEMBL3919646 0.72 SMN1; SMN2 (0.49) ALDH1A1SMN1; SMN2RAB9ANPC1POLB
SCHEMBL7163959 0.72 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2HTTTDP1L3MBTL1
SCHEMBL7443478 0.70 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2HTTTDP1L3MBTL1
SCHEMBL17866316 0.69 HDAC1 (0.49) ALDH1A1POLBTDP1L3MBTL1HDAC1
SCHEMBL19281553 0.69 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2RAB9ANPC1POLB
SCHEMBL465595 0.68 ALDH1A1 (0.63) ALDH1A1POLBTDP1L3MBTL1HPGD
SCHEMBL7417079 0.68 SMN1; SMN2 (0.47) ALDH1A1SMN1; SMN2RAB9ANPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008107677-A2 THIADIAZOLE AND OXADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS SENEXIS LIMITED (GB) 2008-09-12 WO disclosed